DOI QR코드

DOI QR Code

Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening

  • Laidi, Fatna (Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, University Mohammed V) ;
  • Bouziane, Amal (Department of Periodontology, Faculty of Dental Medicine, Biostatistical, Clinical and Epidemiological Research Laboratory, Faculty of Medicine and Pharmacy, University Mohammed V) ;
  • Errachid, Abdelhamid (Institute of Analytical Sciences (ISA), University of Lyon) ;
  • Zaoui, Fatima (Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, University Mohammed V)
  • Published : 2016.02.05

Abstract

Background: The aim of this work was to investigate if serum and salivary auto-antibodies, isotypes IgG and IgM, against HER2 and MUC1 tandem repeat fragments could play a role in breast cancer screening. Materials and Methods: Our case-control study was conducted in breast cancer patients, in early stages (n=29), at the gynecology service, Maternity Souissi Hospital, Rabat, Morocco and healthy woman (n=31). Salivary and serum auto-antibodies against HER2 and MUC1 (tandem repeat) were assessed by enzyme-linked immunosorbent assay (ELISA) and compared between patients and healthy women using the Mann-Whitney U test. A P-value <0.05 was considered to be statistically significant. Results: Our data showed higher expression of all serum and salivary autoantibodies in patients as compared to healthy women p<0.05. However, serum IgM anti-MUC1 expression did not show a significant difference between cases and controls (p=0.79). Similarly, salivary IgG anti-HER2 expression did not differ (p=0.15). The correlation between the different isotypes of antibodies revealed that the highest correlation was between salivary IgG anti-HER2 and salivary IgG anti-MUC1(r=0.65). In fact, we have found in saliva the correlation between autoantibodies anti-MUC1 and anti-HER2 more important than in serum (r=0.59 and r=0. 55). However, the correlation between serum and saliva values for all antibodies was weak. Conclusions: Autoantibodies against HER2 and MUC1 may provide a useful approach in breast cancer screening when using both serum and saliva values.

Keywords

Breast cancer;autoantibodies;HER2;MUC1;saliva;serum

References

  1. Al Kawas S, Rahim ZH, Ferguson DB (2012). Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol, 57, 1-9. https://doi.org/10.1016/j.archoralbio.2011.06.013
  2. Arif S, Qudsia S, Urooj S, et al (2014). Blueprint of quartz crystal microbalance biosensor for early detection of breast cancer through salivaryautoantibodies against ATP6AP1. Biosens Bioelectron, 65, 62-70.
  3. Atoum M, Nimer N, Abdeldayem S, et al (2012). Relationships among serum CA15-3 tumor marker, tnm staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60. https://doi.org/10.7314/APJCP.2012.13.3.857
  4. Begum M, Karim S, Malik A, et al (2012). CA 15-3 (mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 13, 5257-1. https://doi.org/10.7314/APJCP.2012.13.10.5257
  5. Chapman C, Murray A, Chakrabarti J, et al (2007). Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol, 18, 868-3. https://doi.org/10.1093/annonc/mdm007
  6. Chapman CJ, Murray A, McElveen JE, et al (2008). Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax, 63, 228-33. https://doi.org/10.1136/thx.2007.083592
  7. Desmetz C, Lacombe J, Mange A, et al (2011). Autoanticorps et diagnostic precoce des cancers. Med Sci, 27, 633-8.
  8. Evans RL, Pottala JV, Egland KA (2014). Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res, 7, 545-5. https://doi.org/10.1158/1940-6207.CAPR-13-0416
  9. Gendler S, Taylor-Papadimitriou J, Duhig T, et al (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.
  10. Humphrey SP, Williamson RT (2001). A review of saliva: normal composition, flow, and function. J Prosthet Dent, 85, 162-9. https://doi.org/10.1067/mpr.2001.113778
  11. Isla Larrain MT, Colussi AG, Demichelis SO, et al (2013). Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients. Int J Biol Markers, 28, 318-5. https://doi.org/10.5301/jbm.5000036
  12. Kufe DW (2013). MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. Oncogene, 32, 1073-1. https://doi.org/10.1038/onc.2012.158
  13. Laidi F, Bouziane A, Lakhdar A, et al (2014). Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. Onco Targets Ther, 7, 1285-9.
  14. Laidi F, Bouziane A, Lakhdar A, et al (2014). Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients. Asian Pac J Cancer Prev, 15, 4659-2. https://doi.org/10.7314/APJCP.2014.15.11.4659
  15. Lamster IB, Ahlo JK (2007). Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci, 1098, 216-9. https://doi.org/10.1196/annals.1384.027
  16. Lu H, Ladd J, Feng Z, et al (2012). Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res, 5, 1036-3. https://doi.org/10.1158/1940-6207.CAPR-11-0558
  17. Maric P, Ozretic P, Levanat S, et al (2011). Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol, 35, 241-7.
  18. Moazzezy N, Farahany T-Z, Oloomi M, et al (2014). Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8. https://doi.org/10.7314/APJCP.2014.15.4.1685
  19. Murphy MA, O'Leary JJ, Cahill DJ (2012). Assessment of the humoral immune response to cancer. J Proteomics, 75, 4573-9. https://doi.org/10.1016/j.jprot.2012.01.021
  20. Muss HB, Thor AD, Berry DA, et al (1994). c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med, 330, 1260-6. https://doi.org/10.1056/NEJM199405053301802
  21. Pinkhasov J, Alvarez ML, Rigano MM, et al (2011). Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1. Tg mice. Plant Biotechnol J, 9, 991-1. https://doi.org/10.1111/j.1467-7652.2011.00614.x
  22. Porika M, Malotu N, Veldandi U-K, et al (2010). Evaluation of tumor markers in Southern Indian breast cancer patients. Asian Pac J Cancer Prev, 11, 157-9.
  23. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science, 235, 177-2. https://doi.org/10.1126/science.3798106
  24. Sotelo MJ, Garcia-Saenz JA, Manso L, et al (2014). Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. J Cancer Res Ther, 10, 967-2. https://doi.org/10.4103/0973-1482.138017
  25. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8. https://doi.org/10.1128/CVI.00142-10
  26. Tarhan M-O, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum ca15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9. https://doi.org/10.7314/APJCP.2013.14.3.1725
  27. Tarhan Geeraert N, Klausz R, Cockmartin L, et al (2014). Comparison of volumetric breast density estimations from mammography and thorax CT. Phys Med Biol, 59, 4391-9. https://doi.org/10.1088/0031-9155/59/15/4391
  28. Tjemslanda L and Soreide JA (2004). Operable breast cancer patients with diagnostic delay oncological and emotional characteristics. Eur J Surg Oncol, 30, 721-7. https://doi.org/10.1016/j.ejso.2004.05.005
  29. Treon SP, Maimonis P, Bua D, et al (2000). Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 96, 3147-3.
  30. Tse C (2010). sHER-2: a novel marker? Med Nucl, 34, 66-1.
  31. Wang YQ, Zhang HH, Liu CL, et al (2012). Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer. Asian Pac J Cancer Prev, 13, 5557-2. https://doi.org/10.7314/APJCP.2012.13.11.5557
  32. Warnakulasuriya S, Soussi T, Maher R, et al (2000). Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol, 192, 52-7. https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH669>3.0.CO;2-C
  33. Zhang S-J, Hu Y, Qian H-L, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40. https://doi.org/10.7314/APJCP.2013.14.6.3937

Cited by

  1. The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract vol.63, pp.6, 2017, https://doi.org/10.1139/cjm-2016-0603
  2. Electrochemical biosensors for autoantibodies in autoimmune and cancer diseases vol.11, pp.7, 2019, https://doi.org/10.1039/C8AY02742K